Skip to content

Accessibility to GLP-1 Agonists: How Hard is it?

In the realm of diabetes management and weight loss, GLP-1 agonists have emerged as promising treatment options. However, navigating the hurdles of accessibility presents significant challenges for individuals seeking these medications. Understanding the barriers to access is crucial for addressing disparities in diabetes care and obesity treatments.

Understanding GLP-1 Agonists in Weight Loss & Diabetes Treatment

To begin, let’s explore the role of GLP-1 agonists in diabetes treatment and weight management. These medications mimic the action of glucagon-like peptide-1, a hormone that regulates insulin secretion and blood sugar levels. Beyond glycemic control, GLP-1 agonists have shown efficacy in promoting weight loss, making them valuable tools in the management of both diabetes and obesity. From a weight loss perspective, the way these drugs work is crucial to understanding how they aid in losing weight. GLP-1 Agonists have been shown to change appetite and eating habits altogether by slowing down the duration of digestion, leaving GLP-1 users feeling fuller and more likely to consume smaller portions.

A plate depicting word tiles reading "weight loss", one of the more common reasons people seek out the use of GLP-1 agonists, which has led to accessibility issues for some.

The Rising Costs of GLP-1 Agonists

Transitioning to the financial aspect, the rising cost of diabetes treatment compounds the challenge of accessing GLP-1 agonists. Factors such as escalating medication prices and healthcare expenses contribute to the financial strain faced by individuals and healthcare systems. As a result, affordability becomes a significant barrier to accessing these essential medications. Employer funded health care plans have experienced a meteoric rise in claims costs since the introduction of GLP-1 agonists to the market. For more on the impact of the introduction of GLP-1 agonists to healthcare costs, check out Boom in Weight-Loss Drugs to Drive up US Employers’ Medical Costs in 2024 – Mercer.

Accessibility Challenges

Moreover, accessibility issues further exacerbate the hurdles faced by individuals seeking GLP-1 agonist therapy. The current demand for these medications is becoming increasingly difficult for suppliers to keep up with. Additionally, insurance coverage limitations, formulary restrictions, and high out-of-pocket costs create barriers to accessing these medications. These challenges disproportionately affect marginalized communities and those with limited financial resources, widening health disparities in diabetes care.

While the price of GLP-1 agonists remains relatively accessible for the treatment of type 2 diabetes, for those whose insurance plans cover it, those who don’t have coverage are left to pay steep out of pocket costs. Individuals seeking the help of GLP-1 agonists for use as a weight loss aid likely find their insurance also does not cover it, or they don’t meet the requirements for coverage, and they too must deal with staggering prices. Currently GLP-1 agonists cost, on average, between $900-$1,350 per month, leaving health plan sponsors in a precarious position. Most are forced to choose between providing competitive coverage or constraining rising claims costs.

Strategies for Affordability

Despite these obstacles, some strategies do exist to help patients navigate the cost of GLP-1 agonists. Researching insurance coverage options and formularies can provide insight into available benefits. Some health plan sponsors have shifted to the use of educational and companion programs as requirements before providing coverage for GLP-1 agonists. This strategy has shown to increase the likelihood of success for GLP-1 users and the sustainability of their results. Those seeking coverage of GLP-1 agonists can even stand to benefit from lowered co-pays upon completion of these programs.

Exploring patient assistance programs and prescription savings cards can also mitigate out-of-pocket expenses. Engaging in candid discussions with healthcare providers about affordability concerns may also lead to alternative treatment options that better align with patients’ financial circumstances.

Depiction of information pamphlets on diabetes, which GLP-1 agonists were primarily designed to treat.

Patient Perspectives

To gain a comprehensive understanding of the impact of accessibility barriers, it’s essential to consider patient perspectives. Personal stories and testimonials from individuals navigating the complexities of diabetes care shed light on the human side of this issue. GLP-1 agonists have also been useful in treating those with prediabetes.

One such example would be the married couple of Susan and Michael Dixon. Susan, a prediabetic, and Michael, a type 2 diabetic, shared their successful experience with GLP-1 agonists in this article. While prediabetes patients can benefit from GLP-1 agonists, there are other ways to manage or arrest it without the use of GLP-1’s. To learn more about Prediabetes check out one of our earlier posts, Prediabetes: What you Need to Know.

What to Remember

The hurdles to accessing GLP-1 agonists for diabetes treatment and weight loss are multifaceted and impactful, but not insurmountable. As more benefits are discovered about this medication, more will likely be done to for accessibility. Although hurdles do exist to obtaining this medication, there are programs out there that aim to address these issues. Talk to your physician, find out if you meet coverage requirements, and start making lifestyle changes today in preparation. No medication is a silver bullet, and making changes that lead to a healthier life will always serve you well.

About the author